Anaptysbio (ANAB) Other Accumulated Expenses (2016 - 2026)

Anaptysbio (ANAB) has 9 years of Other Accumulated Expenses data on file, last reported at $17.8 million in Q1 2026.

• Quarterly Other Accumulated Expenses changed N/A year-over-year to $17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.8 million (changed N/A YoY) and the FY2025 annual result came in at $16.4 million, down 45.71% from the prior year.
• Other Accumulated Expenses rose to $17.8 million in Q1 2026, from $16.4 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $30.2 million in Q4 2024 to a low of $16.4 million in Q4 2025.
• A 3-year average of $21.5 million and a median of $17.8 million in 2026 frame the typical range for Other Accumulated Expenses.
• The widest YoY moves for Other Accumulated Expenses: up 45.71% in 2025, down 45.71% in 2025.
• Tracing ANAB's Other Accumulated Expenses over 3 years: stood at $30.2 million in 2024, then slumped by 45.71% to $16.4 million in 2025, then increased by 8.47% to $17.8 million in 2026.
• The last three Other Accumulated Expenses figures came in at $17.8 million (Q1 2026), $16.4 million (Q4 2025), and $30.2 million (Q4 2024), per Business Quant data.